JP2023540849A - 三叉神経痛の治療方法 - Google Patents

三叉神経痛の治療方法 Download PDF

Info

Publication number
JP2023540849A
JP2023540849A JP2023505820A JP2023505820A JP2023540849A JP 2023540849 A JP2023540849 A JP 2023540849A JP 2023505820 A JP2023505820 A JP 2023505820A JP 2023505820 A JP2023505820 A JP 2023505820A JP 2023540849 A JP2023540849 A JP 2023540849A
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540849A5 (https=
Inventor
ゲオルク ガリバルディ
Original Assignee
ノエマ ファーマ アクツィエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノエマ ファーマ アクツィエンゲゼルシャフト filed Critical ノエマ ファーマ アクツィエンゲゼルシャフト
Publication of JP2023540849A publication Critical patent/JP2023540849A/ja
Publication of JP2023540849A5 publication Critical patent/JP2023540849A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2023505820A 2020-07-30 2021-07-30 三叉神経痛の治療方法 Pending JP2023540849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30
US63/058,630 2020-07-30
PCT/EP2021/071376 WO2022023519A1 (en) 2020-07-30 2021-07-30 Methods of treatment of trigeminal neuralgia

Publications (2)

Publication Number Publication Date
JP2023540849A true JP2023540849A (ja) 2023-09-27
JP2023540849A5 JP2023540849A5 (https=) 2024-08-06

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505820A Pending JP2023540849A (ja) 2020-07-30 2021-07-30 三叉神経痛の治療方法

Country Status (15)

Country Link
US (2) US20230172922A1 (https=)
EP (1) EP4188370A1 (https=)
JP (1) JP2023540849A (https=)
KR (1) KR20230047132A (https=)
CN (1) CN115989024A (https=)
AR (1) AR123108A1 (https=)
AU (1) AU2021316675A1 (https=)
BR (1) BR112023001621A2 (https=)
CA (1) CA3182457A1 (https=)
CL (1) CL2023000261A1 (https=)
IL (1) IL300124A (https=)
MX (1) MX2023001288A (https=)
PH (1) PH12023550204A1 (https=)
TW (1) TW202220649A (https=)
WO (1) WO2022023519A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004522804A (ja) * 2001-01-05 2004-07-29 イーライ・リリー・アンド・カンパニー 興奮性アミノ酸レセプターアンタゴニスト
JP2006526588A (ja) * 2003-06-05 2006-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー グルタミン酸受容体アンタゴニストであるイミダゾール誘導体
US20090239919A1 (en) * 2008-03-08 2009-09-24 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
JP2010513378A (ja) * 2006-12-21 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ５受容体アンタゴニストの多形
JP2013505262A (ja) * 2009-09-17 2013-02-14 バンダービルト ユニバーシティー ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004522804A (ja) * 2001-01-05 2004-07-29 イーライ・リリー・アンド・カンパニー 興奮性アミノ酸レセプターアンタゴニスト
JP2006526588A (ja) * 2003-06-05 2006-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー グルタミン酸受容体アンタゴニストであるイミダゾール誘導体
JP2010513378A (ja) * 2006-12-21 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ５受容体アンタゴニストの多形
US20090239919A1 (en) * 2008-03-08 2009-09-24 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
JP2013505262A (ja) * 2009-09-17 2013-02-14 バンダービルト ユニバーシティー ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABUSHIK, P. A. ET AL.: "The role of NMDA and mGluR5 receptors in calcium mobilization and neurotoxicity of homocysteine in t", JOURNAL OF NEUROCHEMISTRY, vol. 129, JPN6025037709, 2014, pages 264 - 274, ISSN: 0005828664 *
MCGINITY, J. W. ET AL.: "Oral controlled-release polymeric drug delivery systems", ENGINEERING POLYMER SYSTEMS FOR IMPROVED DRUG DELIVERY, JPN6025037710, 2013, pages 283 - 318, ISSN: 0005686378 *
SOUNG, JI-HYEON ET AL.: "Signal Transduction Mechanisms Underlying Group I mGluR-mediated Increase in Frequency and Amplitude", MOLECULAR PAIN, vol. 5, no. 50, JPN6025037708, 2009, pages 1 - 15, ISSN: 0005828663 *

Also Published As

Publication number Publication date
TW202220649A (zh) 2022-06-01
EP4188370A1 (en) 2023-06-07
CN115989024A (zh) 2023-04-18
AU2021316675A1 (en) 2023-01-19
CL2023000261A1 (es) 2023-09-08
AR123108A1 (es) 2022-10-26
US20230172922A1 (en) 2023-06-08
WO2022023519A1 (en) 2022-02-03
MX2023001288A (es) 2023-04-28
CA3182457A1 (en) 2022-02-03
IL300124A (en) 2023-03-01
PH12023550204A1 (en) 2024-06-24
US20250345320A1 (en) 2025-11-13
BR112023001621A2 (pt) 2023-04-04
KR20230047132A (ko) 2023-04-06

Similar Documents

Publication Publication Date Title
CN108785265B (zh) 杂环化合物和其用途
KR20210117345A (ko) Jak 저해제를 포함하는 제약 조성물
JP2025122066A (ja) 結節性硬化症の治療の方法
JP2008542419A (ja) 神経刺激性ステロイドの医薬組成物及びその使用
CN107072968A (zh) 环苯扎林盐酸盐的低共熔混合物配制剂
KR102515847B1 (ko) 융합된 트리사이클릭 감마-아미노산 유도체의 조성물 및 이의 제조 방법
CN113214209A (zh) 橙皮素与卡马西平共晶物及制备方法和其组合物与用途
JP2020528881A (ja) フェノラミンｇ型結晶、その製造方法並びにその組成物及び用途
JP2023540849A (ja) 三叉神経痛の治療方法
CN109721557B (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
CN110582278A (zh) 药物组合物及其用途
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
CN101684083B (zh) 胍基烷酰胺基取代的四环素衍生物
OA21124A (en) Methods of treatment of trigeminal neuralgia.
TWI659739B (zh) 便秘症之預防或治療藥
CN109721558B (zh) 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途
CN115120588B (zh) 大黄酸与槐果碱共晶物及制备方法和其组合物与用途
CN101863902A (zh) 2-取代苯基-2-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5（4H）-基)乙酸(取代烷基醇)酯的制备方法和用途
CN121226301A (zh) 刺槐素与哌嗪共晶物及制备方法和其组合物与用途
HK40047283B (en) Eutectic formulations of cyclobenzaprine hydrochloride

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331